Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
NCT00362817 is a phase 1/2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. As of 21 Nov 2026, it is completed. It studies Carboplatin and Temozolomide in Brain Metastases and Brain Tumor. The registry lists an enrollment of 17 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2004 and a primary completion date of 31 Jan 2008.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00362817 |
| Status | Completed |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
| Enrollment | 17 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Brain Metastases and Brain Tumor |
| Drugs | Carboplatin and Temozolomide |
| Start | 31 Oct 2004 |
| Primary completion | 31 Jan 2008 |
| Study completion | 29 Feb 2008 |
| Last update posted | 1 Jun 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Herbert Newton, MD
Ohio State University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ohio State University
Columbus
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00362817
Each answer restates registry values shown on this page.
What is NCT00362817?
NCT00362817 is a phase 1/2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. It studies Carboplatin and Temozolomide in Brain Metastases and Brain Tumor.
Who leads NCT00362817?
The registry names Herbert Newton, MD (principal investigator, Ohio State University) as the overall official.
Where does NCT00362817 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00362817 study?
The registered drug and biological interventions are Carboplatin and Temozolomide.
When did NCT00362817 end?
The registry lists a primary completion date of 31 Jan 2008 and a study completion date of 29 Feb 2008. The sponsor last updated the record on 1 Jun 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.